Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III Study of Evenamide Add-on in Treatment-Resistant Schizophrenia
KCT0011508Phase 3Recruiting
- Sponsor
- Myungin Pharm
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of evenamide in schizophrenia, sponsored by Myungin Pharm. Started Apr 2026; status: recruiting.
02
Drugs
evenamide
03
Conditions
schizophrenia
Beyond the preview
Go deeper on KCT0011508.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0011508.